Drug Combination Details
| General Information of the Combination (ID: C96718) | |||||
|---|---|---|---|---|---|
| Name | Apocynin NP Info | + | Edaravone Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | GABPA | Molecule Info | |||
| Up-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male Wistar rats weighing 180-210 g were used in this study. | |||||
| Experimental
Result(s) |
AV and ED prevent CP cardiotoxicity by attenuating oxidative stress and tissue injury, and modulating cytoglobin, and PI3K/Akt/mTOR and Keap1/Nrf2 signaling. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Edaravone and Acetovanillone Upregulate Nrf2 and PI3K/Akt/mTOR Signaling and Prevent Cyclophosphamide Cardiotoxicity in Rats. Drug Des Devel Ther. 2020 Nov 30;14:5275-5288. | |||
